DESCRIPTION

1.Herceptin (Trastuzumab) biosimilar
2.Launched in 2023, the cornerstone drug for HER2+ BC treatment
3.The results of the Ph3 clinical trial indicated that Anruize is highly similar to the original drug Herceptin in terms of clinical efficacy, safety, pharmacokinetics, and immunogenicity
4.Anruize originates from Trastuzumab’s international standard collaborative calibration unit, bringing new high-quality options for clinical anti-HER2 treatment

x

DESCRIPTION

China's first CD20 antibody class I innovative drug. A human-mouse chimeric monoclonal antibody targeting CD20 on the surface of B-cell, leading to B-cell elimination via ADCC and CDC effect. Compared with other anti-CD20 mAbs, HS006 has stronger ADCC effect and volume of distribution at steady state (Vss), which leads to prolongated B-cell elimination and better efficacy

x

DESCRIPTION

Bosimilar of Pertuzumab

x

BR105

A humanized monoclonal antibody targeting macrophage checkpoint SIRPα. BR105 can bind with all common variants of SIRPα and block their interaction with CD47 (the "don't-eat-me" signaling pathway), releasing the break of macrophage anti-tumor activity. BR105 has demonstrated synergistic effect with various anti-TAA therapies in preclinical studies.

x

DESCRIPTION

A humanized monoclonal antibody targeting C-type lectin-like type II transmembrane protein NKG2A. By blocking the interaction between NKG2A and HLA-E, BRY805 demonstrated anti-tumor activity by releasing the break on Natural-killer (NK) cell.

x

DESCRIPTION

A T-cell engaged tri-specific antibody for solid tumor

x

DESCRIPTION

A LIV-1 targeted ADC with small-molecule toxins linked via CysLink™ irreversible chemistry conjugation platform and a highly stable linker. By binding to LIV-1 on the surface of tumor cells, the ADC-target complex enters the tumor cell’s lysosome through endocytosis, releasing small molecule toxins that selectively kill tumor cells.

x

DESCRIPTION

x

DESCRIPTION

x

DESCRIPTION

x